目的:探讨扶正化毒方维持治疗对中晚期非小细胞肺癌(NSCLC)化疗患者生活质量及无进展生存期的影响。方法:将85例中晚期NSCLC患者随机按入院顺序分为对照组42例和观察组各43例。对照组进行对症支持治疗,观察组在对照组治疗的基础上加用扶正化毒方。两组患者直至出现病情进展后终止观察。采用欧洲癌症研究和治疗组织生命质量核心量表(EORTCQLQ-C30);进行治疗前后KPS评分;记录无进展生存期(PFS);检测治疗前后T细胞亚群(CD4+,CD4+,CD8+,CD4+/CD8+)和免疫球蛋白检测(IgG,IgA,IgM)。结果:治疗后观察组躯体功能、角色功能、情绪功能、社会功能和整体生活质量评分均好于对照组(P<0.01);观察组在疲倦、恶心与呕吐、呼吸困难、失眠、食欲丧失维度评分低于对照组(P<0.01);观察组KPS评分提高+稳定率为90.70%,优于对照组的71.43%(P<0.05);观察组无进展生存期(7.3±0.85)个月优于对照组的(4.5±1.08)个月(P<0.01);治疗后观察组CD3+,CD4+,CD4+/CD8+和IgG均较治疗前升高,并高于对照组(P<0.01)。结论:扶正化毒方维持治疗能提高化疗后中晚期非小细胞肺癌(NSCLC)患者的生存质量,延长无进展生存期(PFS),调节免疫功能。 Objective: To investigate the effect of Fuzhenghua DDP on quality of life and progression-free survival in patients with advanced non-small cell lung cancer (NSCLC). Methods: Eighty-five patients with advanced NSCLC were randomly divided into control group (42 cases) and observation group (43 cases). Control group symptomatic supportive treatment, the observation group in the control group based on the treatment plus Fuzheng Huatuo Fang. Two groups of patients until the progression of the disease stopped after the observation. (EORTCQLQ-C30), KPS score before and after treatment, progression-free survival (PFS) were recorded before and after treatment. T cell subsets (CD4 +, CD4 +, CD8 +, CD4 + / CD8 + ) And immunoglobulin detection (IgG, IgA, IgM). Results: After treatment, the body function, role function, emotional function, social function and overall quality of life in the observation group were better than those in the control group (P <0.01). The observation group had significant differences in fatigue, nausea and vomiting, dyspnea, insomnia, loss of appetite (P <0.01). The KPS score of the observation group was increased by 90.70%, which was better than that of the control group (71.43%) (P <0.05). The progression-free survival rate of the observation group was (7.3 ± 0.85) months (4.5 ± 1.08) months in the control group (P <0.01). After treatment, the levels of CD3 +, CD4 +, CD4 + / CD8 + and IgG in the observation group were significantly higher than those in the control group (P <0.01). Conclusion: The treatment of Fuzhenghuidu decoction can improve the quality of life, prolong the progression-free survival time (PFS) and regulate the immune function in patients with advanced non-small cell lung cancer (NSCLC) after chemotherapy.